RCUS
Price
$19.37
Change
+$0.27 (+1.41%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
2.43B
5 days until earnings call
Intraday BUY SELL Signals
TYRA
Price
$20.87
Change
+$0.27 (+1.31%)
Updated
Oct 22 closing price
Capitalization
1.43B
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RCUS vs TYRA

RCUS vs TYRA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
RCUS vs. TYRA commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCUS is a StrongBuy and TYRA is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for RCUS with price predictions
Oct 22, 2026

RCUS in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 21, 2026

RCUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 32 cases where RCUS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 61 cases where RCUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

Following a +7.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCUS advanced for three days, in 219 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCUS as a result. In 77 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for RCUS turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 34 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for RCUS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.242) is normal, around the industry mean (2.973). P/E Ratio (-4.848) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (25.063) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. RCUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for TYRA with price predictions
Oct 22, 2026

TYRA's RSI Indicator ascends from oversold territory

The RSI Indicator for TYRA moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 21 of the 23 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on TYRA as a result. In 83 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for TYRA just turned positive on October 20, 2026. Looking at past instances where TYRA's MACD turned positive, the stock continued to rise in 50 of 56 cases over the following month. The odds of a continued upward trend are 89%.

Following a +1.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where TYRA advanced for three days, in 248 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

TYRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TYRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for TYRA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.057) is normal, around the industry mean (2.973). P/E Ratio (-8.732) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. TYRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
RCUS: Fundamental Ratings
RCUS
OUTLOOK RATING
1..100
32
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
15
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RCUSTYRA
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 1 day ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
78%
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
89%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (RCUS: $19.36 vs. TYRA: $20.60)
Brand notoriety: RCUS and TYRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCUS: 458% vs. TYRA: 72%
Market capitalization -- RCUS: $2.43B vs. TYRA: $1.43B
RCUS [@Biotechnology] is valued at $2.43B. TYRA’s [@Biotechnology] market capitalization is $1.43B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCUS’s FA Score shows that 1 FA rating(s) are green while TYRA’s FA Score has 2 green FA rating(s).

  • RCUS’s FA Score: 1 green, 4 red.
  • TYRA’s FA Score: 2 green, 3 red.
According to our system of comparison, TYRA is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCUS’s TA Score shows that 4 TA indicator(s) are bullish while TYRA’s TA Score has 5 bullish TA indicator(s).

  • RCUS’s TA Score: 4 bullish, 4 bearish.
  • TYRA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, TYRA is a better buy in the short-term than RCUS.

Price Growth

RCUS (@Biotechnology) experienced а -15.16% price change this week, while TYRA (@Biotechnology) price change was +10.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

RCUS is expected to report earnings on Oct 27, 2026.

TYRA is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
RCUS
Daily Signal:
Gain/Loss:
TYRA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with VIR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+1.36%
VIR - RCUS
49%
Loosely correlated
-1.32%
XNCR - RCUS
49%
Loosely correlated
+2.70%
KURA - RCUS
46%
Loosely correlated
-0.20%
NRIX - RCUS
44%
Loosely correlated
-1.96%
BCAX - RCUS
44%
Loosely correlated
-1.68%
More

TYRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TYRA has been loosely correlated with CGEM. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if TYRA jumps, then CGEM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TYRA
1D Price
Change %
TYRA100%
+1.31%
CGEM - TYRA
38%
Loosely correlated
+0.20%
RAPP - TYRA
37%
Loosely correlated
+5.87%
RCUS - TYRA
35%
Loosely correlated
+1.36%
GOSS - TYRA
35%
Loosely correlated
-3.37%
RLAY - TYRA
34%
Loosely correlated
-0.38%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EPRT26.261.37
+5.50%
Essential Properties Realty Trust
HBNB4.940.11
+2.28%
Hotel101 Global Holdings Corp.
PETS1.18-0.01
-0.84%
PetMed Express
BCS22.01-0.59
-2.61%
Barclays PLC
CURR2.21-0.23
-9.43%
Currenc Group Inc